BrePco and Piramal Receive UK MHRA Approval for Neoatricon Paediatric Dopamine Formula
Neoatricon, developed by BrePco Biopharma, is an age-appropriate, ready-to-use, sterile solution available in two concentrations: 1.5 mg/mL in a 30 mL vial and a higher strength of 4.5 mg/mL in a 50 mL vial.
BrePco Biopharma | 24/03/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy